Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Pharmaceutical
India’s Zydus Group has acquired the dermatology brand Melgain from Hyderabad-based Issar Pharma. 8 August 2016
Biotechnology
The drug cost-effectiveness watchdog for England and Wales, the National Institute for Health and Care Excellence (NICE), has published draft guidance recommending apremilast, a drug marketed by US biotech firm Celgene as Otezla, for psoriasis patients. 3 August 2016
Pharmaceutical
India's Sun Pharmaceutical and Spain’s Almirall have announced a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe. 28 July 2016
Biotechnology
At around six weeks after launch of Eli Lilly's interleukin (IL)-17 inhibitor Taltz (ixekizumab), one-third of surveyed dermatologists (n=99) report trialling the latest biologic, according to RealTime Dynamix: Psoriasis. 28 July 2016
Pharmaceutical
Spain's leading drugmaker Almirall has reported that its total revenue in the first half of 2016 was 428.1 million euros ($470.8 million), which is 5% higher than in the same period of 2015. 26 July 2016
Pharmaceutical
Spain’s leading drugmaker Almirall has entered through USA-based Aqua into a global licensing agreement with Patagonia Pharmaceuticals, a specialty US company developing innovative prescription therapies for rare dermatological diseases. 23 July 2016
Biotechnology
Chugai Pharmaceuticals and Switzerland’s Galderma have entered into a global license agreement for nemolizumab (CIM331) the anti-interleukin (IL)-31 receptor A humanized monoclonal antibody created by Chugai. 21 July 2016
Pharmaceutical
Shares in Canadian drugmaker Valeant took an upturn on Wednesday with the news that a US Food and Drug Administration advisory committee had voted unanimously in favor of approving Siliq (brodalumab) for adult patients with moderate-to-severe plaque psoriasis. 20 July 2016
Pharmaceutical
Briefing documents prepared for a US Food and Drug Administration advisory committee have raised concerns on a potential suicide risk involving Siliq (brodalumab), a psoriasis treatment being developed by Canada’s Valeant Pharmaceuticals. 18 July 2016
Pharmaceutical
Pfizer says that positive findings from two pivotal Phase III studies of investigational crisaborole topical ointment 2% (formerly AN2728) have been published in the online issue of the Journal of the American Academy of Dermatology. 14 July 2016
Pharmaceutical
At its July meeting, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded a safety referral on one medicine, and initiated three new safety referrals. 11 July 2016
Biotechnology
Anglo-Swedish drugmaker has entered into agreements with privately-held Danish drugmaker LEO Pharma that support its strategic focus on three main therapy areas; respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease and oncology. 1 July 2016
Biotechnology
Anglo-Swedish drugmaker AstraZeneca has terminated Valeant Pharmaceuticals’ right to develop and commercialize brodalumab in Europe, according to a statement. 1 July 2016
Pharmaceutical
UK-based Sinclair Pharma has had some hugely challenging decisions to make as it has undergone a strategic review over the last 18 months. 25 June 2016
Pharmaceutical
Cipher Pharmaceuticals (TSX: CPH) has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders to fellow Canada-based Edesa Biotech. 22 June 2016
Biotechnology
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness for England and Wales, has today published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the National Health Service. 22 June 2016
Pharmaceutical
Danish privately-held LEO Pharma has launched its psoriasis treatment Enstilar (calcipotriene/betamethasone dipropionate) in the UK. 20 June 2016
Biotechnology
US biotech firm Regeneron Pharmaceuticals and French pharma major Sanofi have announced that their Phase III study of investigational dupilumab to treat adults with severe atopic dermatitis (AD) has met its primary and key secondary endpoints. 6 June 2016
Pharmaceutical
Swedish dermatology specialist Lipidor and Cadila Pharmaceuticals, one of India’s largest privately-held pharma companies, have announced that they will collaborate on a Phase III trial and the joint commercialization of a psoriasis product. 1 June 2016
Pharmaceutical
Almirall has signed, through its recently-acquired Dallas, USA-based subsidiary Thermigen, an exclusive US strategic marketing collaboration agreement for Silhouette Instalift with Sinclair Pharma, a UK specialty pharma company. 20 May 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze